GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Market Cap

FENC (Fennec Pharmaceuticals) Market Cap : $180.42 Mil (As of Mar. 24, 2025)


View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Fennec Pharmaceuticals's share price for the quarter that ended in Sep. 2024 was $5. Fennec Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 27.42 Mil. Therefore, Fennec Pharmaceuticals's market cap for the quarter that ended in Sep. 2024 was $137.11 Mil.

Fennec Pharmaceuticals's quarterly market cap declined from Mar. 2024 ($301.41 Mil) to Jun. 2024 ($166.98 Mil) and declined from Jun. 2024 ($166.98 Mil) to Sep. 2024 ($137.11 Mil).

Fennec Pharmaceuticals's annual market cap increased from Dec. 2021 ($114.46 Mil) to Dec. 2022 ($253.07 Mil) and increased from Dec. 2022 ($253.07 Mil) to Dec. 2023 ($303.24 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Fennec Pharmaceuticals's Enterprise Value for Today is $175.28 Mil.


Fennec Pharmaceuticals Market Cap Historical Data

The historical data trend for Fennec Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Market Cap Chart

Fennec Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 193.72 114.46 253.07 303.24 172.49

Fennec Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303.24 301.41 166.98 137.11 172.49

Competitive Comparison of Fennec Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Fennec Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Market Cap falls into.



Fennec Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Fennec Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$11.22*27.027
=$303.24

Fennec Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$5*27.422
=$137.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fennec Pharmaceuticals  (NAS:FENC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Fennec Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Rosty Raykov director, officer: Chief Executive Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh director 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Robert Andrade officer: Chief Financial Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Marco Maria Brughera director VIALE STEFINI 14, MILANO L6 00000
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel officer: Chief Commercial Officer 1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp 10 percent owner 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook director PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040